TW202229862A - Automatic interpretation system of anti-cellular antibodies and automatic interpretation method thereof capable of automatically analyzing all anti-cellular antibody immunostaining images - Google Patents

Automatic interpretation system of anti-cellular antibodies and automatic interpretation method thereof capable of automatically analyzing all anti-cellular antibody immunostaining images Download PDF

Info

Publication number
TW202229862A
TW202229862A TW109146569A TW109146569A TW202229862A TW 202229862 A TW202229862 A TW 202229862A TW 109146569 A TW109146569 A TW 109146569A TW 109146569 A TW109146569 A TW 109146569A TW 202229862 A TW202229862 A TW 202229862A
Authority
TW
Taiwan
Prior art keywords
classification
cell
analyzed
result
image
Prior art date
Application number
TW109146569A
Other languages
Chinese (zh)
Other versions
TWI773057B (en
Inventor
陳怡行
吳沂達
吳燕晴
黃建中
羅文聰
許瑞愷
陳倫奇
鐘智瑋
Original Assignee
臺中榮民總醫院
東海大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 臺中榮民總醫院, 東海大學 filed Critical 臺中榮民總醫院
Priority to TW109146569A priority Critical patent/TWI773057B/en
Application granted granted Critical
Publication of TWI773057B publication Critical patent/TWI773057B/en
Publication of TW202229862A publication Critical patent/TW202229862A/en

Links

Images

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Image Processing (AREA)

Abstract

The present invention provides an automatic interpretation system of anti-cellular antibodies and an automatic interpretation method thereof, which can automatically analyze all anti-cellular antibody immunostaining images and effectively and correctly interpret cell morphology classifications corresponding to anti-cellular antibody immune images, including a competent level, expert level and mixed patterns of the International Consensus on ANA Patterns (ICAP). Accordingly, the present invention can shorten the time and labor costs of interpretation and increase consistencies of interpretation results and correctness of diagnosis.

Description

抗細胞抗體之自動判讀系統及其自動判讀方法Automatic interpretation system and automatic interpretation method of anti-cell antibody

本發明係有關於一種自體免疫疾病之輔助判讀方法,特別係指一種抗細胞抗體之自動判讀系統及其自動判讀方法。The present invention relates to an auxiliary interpretation method for autoimmune diseases, in particular to an automatic interpretation system for anti-cell antibodies and an automatic interpretation method thereof.

按,抗細胞抗體(anti-cellular antibody, ACA)間接免疫螢光法,又被稱為抗核抗體(anti-nuclear antibody, ANA)間接免疫螢光測定法(indirect immunofluorescence assay,IIFA)係為自體免疫疾病篩檢之黃金標準,其主要係將血清檢體經處理後,於螢光顯微鏡下判斷細胞是否有被螢光染色,若有明顯螢光染色,則被判斷為陽性,並進而根據螢光染色結果提供臨床醫生分析病患可能帶有哪種自體抗體以及何種自體免疫疾病。Press, anti-cellular antibody (ACA) indirect immunofluorescence method, also known as anti-nuclear antibody (anti-nuclear antibody, ANA) indirect immunofluorescence assay (indirect immunofluorescence assay, IIFA) is a self- The gold standard for the screening of immune diseases, which is mainly based on the treatment of serum samples, and the determination of whether the cells are fluorescently stained under a fluorescence microscope. Fluorescent staining results allow clinicians to analyze which autoantibodies and which autoimmune diseases the patient may have.

臨床上判斷分析ANA形態係大多以人工判讀方式進行,且必須要仰賴有經驗之醫檢師判讀才能得到可信賴之結果,惟,ANA間接免疫螢光染色法之檢驗需求量大,而並非各家醫療院所皆有具判讀ANA形態經驗之醫檢師,並且人工判讀需要耗費大量時間,更會對醫檢師眼睛造成傷害;而為了改善人工判讀ANA形態之缺失,目前已有針對ANA形態辨識之自動判讀機器,不過,自動判讀機器僅能判讀6種ANA形態,亦即無法正確判讀混合形態(mixed pattern),且不符合ICAP(International Consensus on ANA Patterns)國際分類法,因此,臨床上仍須以人工判讀方式進行。The clinical judgment and analysis of ANA morphology are mostly carried out by manual interpretation, and must rely on the interpretation of experienced medical examiners to obtain reliable results. However, the ANA indirect immunofluorescence staining method requires a large amount of testing, not every method. All medical institutions have medical examiners with experience in interpreting ANA patterns, and manual interpretation takes a lot of time, which will cause damage to the medical examiners’ eyes. In order to improve the lack of manual interpretation of ANA patterns, there are currently The automatic interpretation machine for identification, however, the automatic interpretation machine can only interpret 6 kinds of ANA patterns, that is, it cannot correctly interpret the mixed pattern, and does not conform to the ICAP (International Consensus on ANA Patterns) international classification method. Therefore, clinically It still has to be done manually.

本發明之主要目的即在於提供一種抗細胞抗體之自動判讀系統及其自動判讀方法,其係能夠自動地分析所有抗細胞抗體免疫染色影像,並且有效且正確地判讀抗細胞抗體免疫影像對應之細胞形態分類,包含國際ANA染色形態共識(International Consensus on ANA Patterns,ICAP)分類標準之勝任級別(competent level)、專家級別(expert level)及混合形態。The main purpose of the present invention is to provide an automatic interpretation system for anti-cellular antibodies and an automatic interpretation method thereof, which can automatically analyze all anti-cellular antibody immunostaining images, and effectively and correctly interpret the cells corresponding to the anti-cellular antibody immune images. Morphological classification, including the competency level (competent level), expert level (expert level) and mixed morphology of the International Consensus on ANA Patterns (ICAP) classification standard.

本發明之另一目的係在於提供一種抗細胞抗體之自動判讀系統及其自動判讀方法,係能夠有效地縮短判讀之時間及人力成本,並且增加判讀結果之一致性及診斷正確性。Another object of the present invention is to provide an automatic interpretation system for anti-cellular antibodies and an automatic interpretation method thereof, which can effectively shorten the time and labor cost of interpretation, and increase the consistency of interpretation results and the accuracy of diagnosis.

緣是,為了達成上述目的,本發明係揭露一種抗細胞抗體之自動判讀系統係包含有一資料模組、一輸入模組及一處理模組,其中,該資料模組中係存放複數筆樣本免疫染色影像之細胞形態分類及其分類特徵,並得定期或不定期地被更新,且得以全部或至少一部資料作為機器學習之輸入來源;該輸入模組係取得自一待測樣本中取得至少一待析免疫染色影像;該處理模組係透過機器學習之演算模式處理來自該資料模組之資料,並演算出一組分類標準,並得分析該待析免疫染色影像之特徵後,再透過該分類標準判斷該待析免疫染色影像之細胞分類形態。The reason is that, in order to achieve the above-mentioned object, the present invention discloses an automatic interpretation system for anti-cellular antibodies, which comprises a data module, an input module and a processing module, wherein the data module stores a plurality of sample immunizations. The cell morphology classification and classification characteristics of the stained image can be updated regularly or irregularly, and all or at least a part of the data can be used as the input source for machine learning; the input module is obtained from a sample to be tested and at least An immunostaining image to be analyzed; the processing module processes the data from the data module through the algorithm model of machine learning, and calculates a set of classification criteria, and after analyzing the characteristics of the immunostaining image to be analyzed, and then through The classification standard determines the cell classification morphology of the immunostaining image to be analyzed.

更進一步來說,該處理模組係具有一運算單元,接收來自該資料模組內之該些樣本免疫染色影像之細胞形態分類及其分類特徵,經運算而建構出一組分類標準,一辨識單元,接收該待析免疫染色影像並進行辨識處理,得到一辨識結果,包含該待析免疫染色影像中之細胞質、細胞核及/或分裂中期細胞之有無、外型、亮度、分佈,及彼此間之關聯性等參數,一分析單元,依據該分類標準分析處理該辨識結果,得到該待析免疫染色影像對應細胞形態分類之一判讀結果。More specifically, the processing module has an operation unit, which receives the cell morphology classification and classification characteristics of the immunostaining images of the samples from the data module, and constructs a set of classification standards through operation to identify a set of classification criteria. a unit that receives the immunostaining image to be analyzed and performs identification processing to obtain an identification result, including the presence or absence, appearance, brightness, and distribution of cytoplasm, nucleus and/or metaphase cells in the immunostained image to be analyzed, and the relationship between them An analysis unit analyzes and processes the identification result according to the classification standard, and obtains an interpretation result of the cell morphology classification corresponding to the immunostaining image to be analyzed.

又,該分析單元更包含有一初判讀部及一終判讀部;其中,該初判讀部係依據該分類標準分析該辨識結果,得到一初判結果;該終判讀部係依據一預定閥值或是多數決演算法分析該初判結果,產出該判讀結果。In addition, the analysis unit further includes a preliminary judgment part and a final judgment part; wherein, the preliminary judgment part analyzes the identification result according to the classification standard to obtain a preliminary judgment result; the final judgment part is based on a predetermined threshold or It is the majority decision algorithm that analyzes the initial judgment result and produces the judgment result.

其中,該分類特徵係包含有細胞質、細胞核及分裂中期細胞之有無、數量、比例、亮度、分佈、外型,及彼此間之關聯性等。Among them, the classification features include the presence or absence of cytoplasm, nucleus and metaphase cells, number, proportion, brightness, distribution, appearance, and their relationship with each other.

其中,該輸入模組係包含有一影像成像單元,用以自該待測樣本中取得一預定數量之待析免疫染色影像。Wherein, the input module includes an image imaging unit for obtaining a predetermined number of immunostaining images to be analyzed from the sample to be tested.

本發明之另一實施例中係揭露一種抗細胞抗體之自動判讀方法,其係提供一細胞形態分類標準,透過該細胞形態分類標準分析該待析樣本及其待析參數,進而判讀出該待析樣本所對應之細胞形態分類。Another embodiment of the present invention discloses an automatic interpreting method for anti-cellular antibodies, which provides a cell morphology classification standard, analyzes the sample to be analyzed and its parameters to be analyzed through the cell morphology classification standard, and then judges the target to be analyzed. The morphological classification of the cells corresponding to the samples was analyzed.

其中,該待析樣本係為以一預定抗體進行免疫細胞染色之影像。The sample to be analyzed is an image of immune cells stained with a predetermined antibody.

於本發明之一實施例中,判讀該待析樣本之步驟更包含有:In an embodiment of the present invention, the step of interpreting the sample to be analyzed further includes:

判斷該待析樣本之染色結果,若細胞核、細胞質及分裂中期細胞未被染色,則判斷該待析樣本係為無反應(Non-reactive,AC-0),若細胞核、細胞質及分裂中期細胞有被染色,則比對該細胞形態分類標準而得到一分類候選結果,其中,當該待析樣本包含有多種免疫細胞染色形態時,該分類候選結果中之細胞形態分類為出現機率大於一預定數值者,如0.5。Determine the staining results of the sample to be analyzed. If the nucleus, cytoplasm, and metaphase cells are not stained, the sample to be analyzed is judged to be Non-reactive (AC-0). If the nucleus, cytoplasm, and metaphase cells have is stained, a classification candidate result is obtained by comparing the cell morphology classification criteria, wherein, when the sample to be analyzed contains a variety of immune cell staining morphology, the cell morphology classification in the classification candidate result is classified as having a probability greater than a predetermined value. , such as 0.5.

分析該分類候選結果,當該分類候選結果僅包含單一細胞分類形態時,判讀該待析樣本之分類結果為該分類候選結果;而當該分類候選結果包含多個細胞分類形態,則先分析該分類候選結果中是否包含有AC-1、AC-2及/或AC-4之細胞形態分類,若有AC-2、及AC-1及/或AC-4,則需排除AC-1及/AC-4,將AC-2列入初分類結果,若無AC-2,但有AC-1,將AC-1納入該待析樣本之初分類結果,並且依據一預定閥值,自其他細胞分類形態中篩選出超出該預定閥值之細胞分類形態,作為該待析樣本之初分類結果,若無AC-2及AC-1,依據該定閥值,自該些細胞分類形態中篩選出超出該預定閥值之細胞分類形態,作為該待析樣本之初分類結果;其中,該預定閥值係為細胞分類形態出現之機率,如預定閥值係可設定為出現機率為大於等於0.5。Analyze the classification candidate result, when the classification candidate result contains only a single cell classification form, interpret the classification result of the sample to be analyzed as the classification candidate result; and when the classification candidate result includes multiple cell classification forms, analyze the classification first. Whether the classification candidate results include the cell morphology classification of AC-1, AC-2 and/or AC-4, if AC-2, and AC-1 and/or AC-4 are present, AC-1 and/or AC-1 should be excluded AC-4, include AC-2 in the initial classification result, if there is no AC-2, but there is AC-1, include AC-1 in the initial classification result of the sample to be analyzed, and according to a predetermined threshold, from other cells Screen out the cell classification patterns that exceed the predetermined threshold from the classification patterns, as the initial classification result of the sample to be analyzed. If there are no AC-2 and AC-1, according to the predetermined threshold, screen out the cell classification patterns from the cell classification patterns. The cell classification pattern that exceeds the predetermined threshold value is used as the initial classification result of the sample to be analyzed; wherein, the predetermined threshold value is the probability of the appearance of the cell classification pattern. For example, the predetermined threshold value can be set to be greater than or equal to 0.5.

分析該初分類結果,其中,若該初分類結果僅包含單一細胞分類形態時,則判讀該待析樣本之分類結果為初分類結果;而當該初分類結果為在不同影像中包含複數個細胞分類形態時,則分析是否符合細胞形態分類中之混合形態,意即將細胞分類形態出現次數大於或等於2者納入分類結果,若分類結果中含有2種以上的細胞分類形態時,則該待析樣本之分類結果係為混合形態。Analyze the preliminary classification result, wherein, if the preliminary classification result only includes a single cell classification form, then interpret the classification result of the sample to be analyzed as the preliminary classification result; and when the preliminary classification result contains multiple cells in different images When classifying morphology, analyze whether it conforms to the mixed morphology in the classification of cell morphology, which means that the number of occurrences of cell classification morphology is greater than or equal to 2 is included in the classification result. The classification results of the samples are mixed patterns.

本發明係揭露一種抗細胞抗體之自動判讀系統及其自動判讀方法,其係透過輸入大量抗細胞抗體免疫影像、其分類特徵及其細胞分類形態至處理模組,使處理模組透過機器學習或深度學習建立一套細胞形態分類標準,並且分析模組係得依據該細胞形態分類標準判讀待析樣本所對應之細胞形態分類,以達到自動判讀待析樣本之細胞形態分類之功效,同時也能夠達到縮短判讀時間、增進判讀效率及準確度之功效。The present invention discloses an automatic interpretation system of anti-cellular antibodies and an automatic interpretation method thereof. By inputting a large number of anti-cellular antibody immune images, their classification characteristics and cell classification patterns into a processing module, the processing module can be processed through machine learning or Deep learning establishes a set of cell morphology classification standards, and the analysis module has to interpret the cell morphology classification corresponding to the sample to be analyzed according to the cell morphology classification standard, so as to achieve the effect of automatically interpreting the cell morphology classification of the sample to be analyzed. To achieve the effect of shortening the interpretation time, improving the efficiency and accuracy of the interpretation.

本發明所揭「機器學習」,係指一種透過機器辨識大量樣本、資料、經驗等資訊,並從中獲得特徵,藉以訓練機器建立運作模式或規則之演算法,進而能夠達到機器具有人工智慧的目的。"Machine learning" disclosed in the present invention refers to an algorithm that recognizes a large number of samples, data, experience and other information through a machine, and obtains features from it, thereby training the machine to establish an operation mode or an algorithm, thereby achieving the purpose of the machine having artificial intelligence .

本發明所揭「深度學習」,係為機器學習之一環,惟,若應用於影像類型等資料,與機器學習之差異在於,深度學習係省取提取特徵之步驟,直接透過卷積之方式提取特徵後進行分類(意即建立出演算規則),其中,最具代表性之深度學習演算法為卷積神經網絡(Convolutional Neural Network,CNN),其包含許多不同架構。而如同本發明所屬技術領域且具通常知識者所周知者,卷積神經網絡包含許多不同架構,例如VGG19、ResNet50V2、DenseNet121、MobileNetV2、Xception、InceptionResNetV2。The "deep learning" disclosed in the present invention is a part of machine learning. However, if it is applied to data such as image types, the difference from machine learning is that deep learning omits the step of extracting features and directly extracts features through convolution. After the features are classified (meaning to establish the algorithmic rules), the most representative deep learning algorithm is the Convolutional Neural Network (CNN), which contains many different architectures. As is known to those of ordinary skill in the art to which the present invention pertains, convolutional neural networks include many different architectures, such as VGG19, ResNet50V2, DenseNet121, MobileNetV2, Xception, InceptionResNetV2.

本發明所揭「間接免疫螢光測定法(indirect immunofluorescence assay,IIFA)」,係為本發明所屬技術領域周知用以於人類上皮細胞篩選出自體抗體之主要診斷工具,並且可作為全身性自體免疫疾病(systemic autoimmune rheumatic diseases, SARD)之黃金標準,例如紅斑狼瘡(systemic lupus erythematosus, SLE)、薛格連氏症候群(Sjogren's syndrome, SjS)、系統性硬化症(systemic sclerosis, SSc)。而透過HEp-2細胞(human epithelial cells)經間接免疫螢光測定所得圖像提供臨床相關訊息,可作為後續抗原特異性檢測之依據。The "indirect immunofluorescence assay (IIFA)" disclosed in the present invention is a major diagnostic tool known in the art for screening autoantibodies from human epithelial cells, and can be used as a systemic autoantibody The gold standard for systemic autoimmune rheumatic diseases (SARD), such as systemic lupus erythematosus (SLE), Sjogren's syndrome (SjS), and systemic sclerosis (SSc). The images obtained by indirect immunofluorescence measurement of HEp-2 cells (human epithelial cells) provide clinically relevant information, which can be used as the basis for subsequent antigen-specific detection.

本發明所揭「國際ANA染色形態共識(International Consensus on ANA Patterns,ICAP)」,係為ANA形態之國際分類法,目前已經分出29種具代表性的形態,其中,細胞形態被分為三大類:細胞核形態、細胞質形態、有絲分裂形態,並每種形態均已被定義和詳細描述,如下表1至表3所示,;而細胞形態更被分為勝任級別(competent level)與專家級別(expert level),以臨床上進行人工判讀來說,醫檢師至少需要識別所有勝任級別之細胞形態。The "International Consensus on ANA Patterns (ICAP)" disclosed in the present invention is an international classification method for ANA patterns. At present, 29 representative patterns have been identified. Among them, cell patterns are divided into three types. Major categories: nuclear morphology, cytoplasmic morphology, mitotic morphology, and each morphology has been defined and described in detail, as shown in Tables 1 to 3 below; and cell morphology is further divided into competency level (competent level) and expert level ( expert level), in terms of clinical manual interpretation, medical examiners need to identify at least the cell morphology of all competency levels.

表1:細胞核染色之形態與其特徵 分類 特徵描述 AC-1 間期細胞核質均勻染(Nuclear homogeneous),分裂中期細胞染色質也均勻染。 AC-2 間期細胞核質緻密小顆粒染(有些區域緻密,有些區域鬆散),分裂中期細胞染色質也緻密小顆粒染。 AC-3 間期細胞核質內多個(40-80/cell)離散的亮點,分裂中期細胞染色質也多個(40-80/cell)離散的亮點。 AC-4 間期細胞核質內細緻密點染(核仁有的有染有的沒染),分裂中期細胞染色質沒有染。 AC-5 間期細胞核質內大粗糙顆粒染(核仁有的有染有的沒染),分裂中期細胞染色質沒有染。 AC-6 間期細胞核質內多個(6-20/cell)可數離散的亮點。 AC-7 間期細胞核質內少量(1-6/cell)可數離散的亮點。 AC-8 間期細胞核仁內均勻亮染,分裂中期細胞染色質沒染。 AC-9 間期細胞核仁不規則亮染,像土塊鬆散脫落(Cajal bodies),分裂中期細胞染色質會較亮。 AC-10 間期細胞核仁點狀亮,分裂中期細胞染色質內可見一些小亮點 (NOR90)。 AC-11 間期細胞核質均勻染,外圍特別亮,細胞交界處也特別亮,分裂中期細胞染色質沒染。 AC-12 間期細胞細胞核外圍點狀亮染,細胞交界處也特別亮,分裂中期細胞染色質沒染。 AC-13 間期細胞根據不同細胞時期,不同細胞核質內多形性的亮度、大小、顆粒皆不同的亮染,分裂中期細胞染色質沒染。 AC-14 根據不同細胞時期,細胞核質內有不同的亮度的染色,分裂中期細胞染色質有著絲粒(centromere)。 AC-29 符合下列五項特徵 1.     間期細胞出現AC4 態樣(Nucleoplasm fine speckled)及其特徵。 2.     有絲分裂細胞染色質有亮染(AC1特徵)。 3.     染色質裡面可以看到NORs(有絲分裂細胞染色質內的小亮點)。 4.     細胞質有染。 5.     核仁有染。 Table 1: Morphology and characteristics of nuclear staining Classification Feature description AC-1 The nuclear homogeneous staining of interphase cells (Nuclear homogeneous), the chromatin of metaphase cells is also homogeneous staining. AC-2 The nucleoplasm of interphase cells is densely stained with small granules (some areas are dense and some areas are loose), and the chromatin of metaphase cells is also densely stained with small granules. AC-3 There are multiple (40-80/cell) discrete bright spots in the nucleoplasm of interphase cells, and multiple (40-80/cell) discrete bright spots in the chromatin of metaphase cells. AC-4 The nucleoplasm of interphase cells is finely and densely stained (some nucleoli are stained and some are not stained), and the chromatin of metaphase cells is not stained. AC-5 The large rough granules in the nucleoplasm of interphase cells are stained (some nucleoli are stained and some are not stained), and the chromatin of metaphase cells is not stained. AC-6 Multiple (6-20/cell) countable discrete bright spots in the nucleoplasm of interphase cells. AC-7 A few (1-6/cell) countable discrete bright spots in the nucleoplasm of interphase cells. AC-8 The nucleolus of interphase cells is uniformly brightly stained, and the chromatin of metaphase cells is not stained. AC-9 The nucleoli of interphase cells are irregularly brightly stained, like loose clods (Cajal bodies), and the chromatin of metaphase cells will be brighter. AC-10 The nucleoli of interphase cells are punctately bright, and some small bright spots (NOR90) can be seen in the chromatin of metaphase cells. AC-11 The nucleoplasm of interphase cells is uniformly stained, the periphery is particularly bright, and the cell junction is also particularly bright, and the chromatin of metaphase cells is not stained. AC-12 The nuclei of interphase cells were punctately brightly stained, and the cell junction was also particularly bright. The chromatin of metaphase cells was not stained. AC-13 Interphase cells were brightly stained according to different cell stages, and the brightness, size and granules of different nucleoplasmic pleomorphisms were different, and the chromatin of metaphase cells was not stained. AC-14 According to different cell stages, there are different brightness staining in the nucleoplasm, and the chromatin of metaphase cells is centromere. AC-29 Meet the following five characteristics 1. Interphase cells appear AC4 (Nucleoplasm fine speckled) and its characteristics. 2. The chromatin of mitotic cells is brightly stained (AC1 characteristic). 3. NORs (small bright spots in the chromatin of mitotic cells) can be seen inside the chromatin. 4. Cytoplasm is stained. 5. The nucleolus is stained.

表2:細胞質染色之形態與其特徵 分類 特徵描述 AC-15 細胞核纖維線狀染(fibrillar linear)。 AC-16 細胞質纖維絲狀染,細胞核邊緣局部會很亮。 AC-17 細胞質纖維短段染。 AC-18 細胞質許多離散亮點。 AC-19 細胞質雲霧狀均勻染。 AC-20 細胞質細緻亮顆粒。 AC-21 細胞質粗糙顆粒纖維染。 AC-22 細胞質、細胞核周圍某一端,帶狀不連續的點或顆粒亮染。 AC-23 細胞質棒狀+環狀染。 Table 2: Morphology and characteristics of cytoplasmic staining Classification Feature description AC-15 Nuclear fiber linear staining (fibrillar linear). AC-16 The cytoplasmic fibers are filamentous, and the edge of the nucleus will be bright locally. AC-17 Cytoplasmic fibers were stained with short segments. AC-18 Many discrete bright spots in the cytoplasm. AC-19 The cytoplasm was cloudy and uniformly stained. AC-20 The cytoplasm is finely granular. AC-21 The cytoplasm was stained with coarse granular fibers. AC-22 At one end of the cytoplasm, around the nucleus, the band-like discontinuous dots or granules are brightly stained. AC-23 Cytoplasm rod-shaped + circular staining.

表3:分裂細胞染色之形態與其特徵 分類 特徵描述 AC-24 分裂中期細胞旁兩側亮點或細胞質的中心體(centrosome)處亮染。 AC-25 分裂中期細胞裡像雨傘狀(spindle fibers)的分開亮染,核質不一定有染(核質有染的可以歸為AC26 NuMa-like pattern)。 AC-26 分裂中期細胞裡像雨傘狀的分開亮染跟AC24很像,但核質需有染(speckled AC4)。 AC-27 分裂中期細胞快結束時細胞間的亮染。 AC-28 只有分裂中期細胞的染色體有染,間期細胞都沒有染。 Table 3: Morphology and characteristics of dividing cell staining Classification Feature description AC-24 Bright spots on both sides of the metaphase cells or at the centrosome of the cytoplasm. AC-25 Separate bright staining of spindle fibers in metaphase cells, not necessarily nucleocytoplasmic staining (nucleocytoplasmic staining can be classified as AC26 NuMa-like pattern). AC-26 Umbrella-like separate bright stains in metaphase cells are very similar to AC24, but nucleoplasmic staining is required (speckled AC4). AC-27 Bright staining between cells near the end of metaphase. AC-28 Only the chromosomes of metaphase cells were stained, and no interphase cells were stained.

本發明所使用之自動影像擷取設備(NOVA View)用以觀察細胞圖像之激發波長為400nm(DAPI)和490nm(FITC)。NOVA View軟體利用DAPI螢光定位HEp-2細胞並聚焦,並以FITC信號為基礎進行圖像分析;針對每個盤中每孔皆至少要獲取3張細胞圖像,並且,每張細胞圖像必須包含有至少25個間期細胞(interphase)及2個有絲分裂(中期)細胞;而該軟體透過FITC圖像測出平均強度之單位為光強度單位(LIU),其係用以區分正樣本和負樣本,另藉由特定模式之稀釋曲線,可以將測得之LIU轉換為估計的終點滴度。根據先前研究指出,細胞染色影像以NOVA View自動影像擷取設備於間接免疫螢光(IIF)1:80篩選稀釋度下與以螢光顯微鏡透過人工判讀已經達到高度一致性。The excitation wavelengths of the automatic image capture device (NOVA View) used in the present invention to observe cell images are 400 nm (DAPI) and 490 nm (FITC). NOVA View software uses DAPI fluorescence to locate and focus HEp-2 cells, and perform image analysis based on the FITC signal; at least 3 cell images are acquired for each well in each plate, and each cell image is Must contain at least 25 interphase cells (interphase) and 2 mitotic (metaphase) cells; and the software measures the average intensity of the FITC image in light intensity units (LIU), which is used to distinguish positive samples from For negative samples, the measured LIU can be converted into an estimated endpoint titer by means of a mode-specific dilution curve. According to previous studies, cell staining images with NOVA View automatic image acquisition equipment at a 1:80 screening dilution of indirect immunofluorescence (IIF) have achieved high consistency with manual interpretation with fluorescence microscopy.

以下,為能更進一步說明本發明,將茲舉若干實施例並搭配圖式做詳細說明如後。Hereinafter, in order to further illustrate the present invention, several embodiments are given and described in detail with the drawings as follows.

請參圖1,本發明第一實施例所揭抗細胞抗體之自動判讀系統(10),其主要包含有一資料模組(20)、一輸入模組(30)及一處理模組(40),其中:Referring to FIG. 1, the automatic interpretation system (10) of anti-cellular antibodies disclosed in the first embodiment of the present invention mainly includes a data module (20), an input module (30) and a processing module (40) ,in:

該資料模組(20)係存放有複數樣本免疫染色影像之細胞形態分類及其分類特徵,其中,該分類特徵係包含有細胞質、細胞核及分裂中期細胞之有無、數量、比例、亮度、分佈、外型,及彼此間之關聯性等,而該些樣本免疫染色影像之細胞形態分類係得為自動影像擷取設備進行判讀之結果、人工判讀之結果,亦或綜合機器及人工判讀所得之結果。The data module (20) stores the cell morphology classification and classification features of the immunostaining images of the plurality of samples, wherein the classification features include the presence or absence of cytoplasm, nuclei and metaphase cells, number, proportion, brightness, distribution, appearance, and their relationship with each other, and the cell morphology classification of the immunostaining images of these samples may be the result of interpretation by automatic image capture equipment, the result of manual interpretation, or the result of combined machine and manual interpretation. .

該輸入模組(30)係包含有一影像成像單元(31),自該待測樣本中取得數量至少為3之待析免疫染色影像;更進一步來說,該輸入模組(30)係得更包含有一影像調整單元(32),調整該待析免疫染色影像之像素、強度、亮度、尺寸、色調或其他與影像顯示相關之參數值,例如移除該待析免疫染色影像中不必要之顏色,使經處理後之該待析免疫染色影像中僅呈現之單一顏色的免疫染色結果。The input module (30) includes an image imaging unit (31) for obtaining at least three immunostaining images to be analyzed from the sample to be tested; further, the input module (30) is more It includes an image adjustment unit (32) for adjusting the pixel, intensity, brightness, size, tone or other parameter values related to image display of the immunostained image to be analyzed, such as removing unnecessary colors in the immunostained image to be analyzed , so that only a single color of the immunostaining result appears in the immunostained image to be analyzed after processing.

該處理模組(40)係具有一運算單元(41),以該資料模組(20)內之該些樣本免疫染色影像之細胞形態分類及其分類特徵作為輸入資料而一預定演算模型進行經運算,輸出一分類標準,一辨識單元(42),接收各該待析免疫染色影像並進行辨識處理,輸出一辨識結果,其中,該辨識結果包含有該待析免疫染色影像中之細胞質、細胞核及/或分裂中期細胞之有無、外型、亮度、分佈,及彼此間之關聯性等參數,一分析單元(43),依據該分類標準分析處理該辨識結果,得到該待析免疫染色影像對應細胞形態分類之一判讀結果;The processing module (40) has an arithmetic unit (41), which uses the cell morphology classification and the classification characteristics of the immunostaining images of the samples in the data module (20) as input data, and a predetermined calculation model performs processing operation, outputting a classification standard, an identification unit (42), receiving each immunostaining image to be analyzed and performing identification processing, and outputting an identification result, wherein the identification result includes cytoplasm and nucleus in the immunostaining image to be analyzed and/or parameters such as presence or absence, appearance, brightness, distribution, and relationship between metaphase cells, an analysis unit (43), analyzes and processes the identification result according to the classification standard, and obtains the corresponding immunostaining image to be analyzed. Interpretation results of one of the cell morphological classifications;

其中,該分析單元(43)係更包含有一初判讀部(431),依據該分類標準分析該辨識結果,得到一初判結果,一終判讀部(432),依據一預定閥值篩選出該初判結果,並得更以多數決演算法產出該判讀結果(亦可稱為終判結果)。Wherein, the analysis unit (43) further includes a preliminary judgment part (431), which analyzes the identification result according to the classification standard to obtain a preliminary judgment result, and a final judgment part (432), which filters out the identification result according to a predetermined threshold The preliminary judgment result, and the judgment result (also called the final judgment result) must be produced by the majority decision algorithm.

透過上述元件之組成,本發明第一實施例中所揭抗細胞抗體之自動判讀系統(10)係以該資料模組儲存大量抗細胞抗體免疫影像及其細胞形態分類結果、特徵等資料,並且,該資料模組(20)之資料能夠即時地被更新,再將該資料模組(20)內之資料作為輸入資料,使該運算單元(41)能夠透過一預定機器學習演算法或是模型建構出與ANA 細胞形態相關之一分類標準,而該分類標準係包含有各細胞形態分類相對應之特徵、判讀待析影像之步驟及流程等;因此,當該輸入單元(30)獲得該些待析免疫染色影像後,該辨識單元(42)會先進行辨識處理,而後該分析單元(43)再根據該分類標準分析該辨識結果,以產出各該待析免疫染色影像之判讀結果,並得對應出一預定之細胞形態分類,藉此而能提供予臨床醫療作為後續治療手段或是疾病判斷之基礎,以縮短判讀ANA IIFA 影像所需成本,及能夠達到自動化輔助判斷自體免疫疾病之功效。Through the composition of the above-mentioned elements, the automatic interpretation system (10) of the anti-cellular antibody disclosed in the first embodiment of the present invention uses the data module to store a large number of anti-cellular antibody immune images and cell morphology classification results, characteristics and other data, and , the data of the data module (20) can be updated in real time, and then the data in the data module (20) is used as input data, so that the operation unit (41) can pass a predetermined machine learning algorithm or model A classification standard related to ANA cell morphology is constructed, and the classification standard includes the corresponding characteristics of each cell morphology classification, the steps and processes of interpreting the image to be analyzed, etc.; therefore, when the input unit (30) obtains these After the immunostaining images to be analyzed, the identification unit (42) will first perform identification processing, and then the analyzing unit (43) will analyze the identification results according to the classification criteria to generate interpretation results of the immunostained images to be analyzed, It can also correspond to a predetermined cell morphology classification, which can be provided to clinical medical treatment as a follow-up treatment method or a basis for disease judgment, so as to shorten the cost of interpreting ANA IIFA images, and achieve automatic assistance in judging autoimmune diseases. effect.

請參圖2,於本發明第二實施例中係揭露一種抗細胞抗體之自動判讀方法,其包含以下步驟:Referring to FIG. 2, a second embodiment of the present invention discloses an automatic interpretation method for anti-cellular antibodies, which includes the following steps:

步驟101:輸入一待析樣本。Step 101: Input a sample to be analyzed.

其中,該待析樣本係為至少一免疫細胞染色影像。Wherein, the sample to be analyzed is at least one immune cell staining image.

步驟102:處理該待析樣本,得到一待析參數。Step 102: Process the sample to be analyzed to obtain a parameter to be analyzed.

其中,該待析參數包含有細胞質、細胞核及/或分裂中期細胞之染色結果、外型、亮度、分佈,及彼此間之關聯性等。Wherein, the parameters to be analyzed include staining results, appearance, brightness, distribution of cytoplasm, nuclei and/or metaphase cells, and their correlation with each other.

步驟103:提供一細胞形態分類標準。Step 103: Provide a cell morphology classification standard.

其中,該細胞形態分類標準係由複數已知免疫染色影像之細胞形態分類及其分類特徵經運算處理而得者,並且,該些已知免疫染色影像係得於運算處理前先進行影像擴增處理或/及影像調整處理,以提高該細胞形態分類標準之準確性。Wherein, the cell morphology classification standard is obtained from the cell morphology classification and its classification characteristics of a plurality of known immunostaining images through operation processing, and these known immunostaining images are obtained by performing image amplification before operation processing. Processing or/and image adjustment processing to improve the accuracy of the cell morphology classification criteria.

步驟104:依據該細胞形態分類標準,對該待析參數進行分析處理,得到該待析樣本對應之細胞形態分類。Step 104 : according to the cell shape classification standard, analyze and process the parameters to be analyzed to obtain the cell shape classification corresponding to the sample to be analyzed.

更進一步來說,如圖3所示,步驟104中更包含有以下步驟:Further, as shown in FIG. 3 , step 104 further includes the following steps:

步驟104-1:依序判斷該待析樣本中之細胞核、細胞質及分裂中期細胞之染色情形。Step 104-1: Sequentially determine the staining status of the nucleus, cytoplasm and metaphase cells in the sample to be analyzed.

若細胞核、細胞質及分裂中期細胞都沒有被染色,則判斷該待析樣本係為無反應(Non-reactive),輸出AC-0之判讀結果;If the nucleus, cytoplasm and metaphase cells are not stained, the sample to be analyzed is judged to be non-reactive, and the interpretation result of AC-0 is output;

若為細胞核、細胞質及分裂中期細胞中至少任一有被染色,則根據該細胞形態分類標準,以不同部位顯示染色結果為基礎進一步分析該待析參數後,得到一分類候選結果,其中,該分類候選結果會包含至少一細胞形態分類。If at least any one of the nucleus, cytoplasm and metaphase cells is stained, then according to the cell morphology classification standard, the parameters to be analyzed are further analyzed based on the staining results displayed in different parts, and a classification candidate result is obtained, wherein the The classification candidate results will include at least one cell morphology classification.

舉例來說,若細胞核沒被染色,但細胞質有被染色,則需分析細胞質之圖樣特徵,並且再分析分裂中期細胞是否有出現特殊特徵,例如:AC-24具有中心體亮染之特徵、AC-25具有分裂中期細胞裡像雨傘狀的分開亮染之特徵;For example, if the nucleus is not stained, but the cytoplasm is stained, it is necessary to analyze the pattern characteristics of the cytoplasm, and then analyze whether there are special characteristics of metaphase cells, such as: AC-24 has the characteristics of bright centrosome staining, AC -25 has the characteristics of umbrella-like separate bright dyes in metaphase cells;

若細胞核被染色,但細胞質沒被染色,則需先找到分裂中期細胞,並分析細胞核之圖樣,再分析分裂中期細胞是否有出現特殊特徵及細胞重疊或是交界處有無特殊特徵,如AC-11具有平滑細胞外圍亮染且細胞交界處特別亮之特徵、AC-12具有細胞核外圍點狀亮染且細胞交界處特別亮之特徵、AC-27具有細胞間橋(intercellular bridge)之特徵;If the nucleus is stained, but the cytoplasm is not stained, you need to find the metaphase cells first, analyze the pattern of the nucleus, and then analyze whether there are special features in the metaphase cells and whether the cells overlap or whether there are special features at the junction, such as AC-11 It has the characteristics of bright staining at the periphery of smooth cells and particularly bright at the cell junction, AC-12 has the characteristics of punctate bright staining at the periphery of the nucleus and particularly bright at the cell junction, and AC-27 has the characteristics of intercellular bridge;

若細胞核及細胞質皆有被染色,先找出分裂中期細胞,再分析核質之圖樣、分裂中期細胞是否有出現特殊特徵及細胞重疊或是交界處有無特殊特徵。If both the nucleus and cytoplasm are stained, first identify the metaphase cells, and then analyze the pattern of the nucleus and cytoplasm, whether there are special features in the metaphase cells, and whether there are special features in the overlapping cells or at the junction.

步驟104-2:分析該分類候選結果。Step 104-2: Analyze the classification candidate result.

當該分類候選結果僅包含單一細胞分類形態時,判讀該待析樣本之分類結果為該分類候選結果;When the classification candidate result contains only a single cell classification form, interpret the classification result of the sample to be analyzed as the classification candidate result;

當該分類候選結果包含多個細胞分類形態,則先分析該分類候選結果中是否包含有AC-2之細胞形態分類,若該分類候選結果包含有AC-2,判讀該待析樣本之分類結果為AC-2,若該分類候選結果中不包含AC-2,再分析該待析樣本之分類候選結果是否包含有AC-1之細胞分類形態,若有該分類候選結果中包含有AC-1,將AC-1納入該待析樣本之初分類結果,並且依據一預定閥值,自其他細胞分類形態中篩選出超出該預定閥值之細胞分類形態,作為該待析樣本之初分類結果,反之,若該分類候選結果不包含有AC-1,依據該預定閥值,自該些細胞分類形態中篩選出超出該預定閥值之細胞分類形態,作為該待析樣本之初分類結果;When the classification candidate result contains multiple cell classification forms, first analyze whether the classification candidate result contains the cell shape classification of AC-2. If the classification candidate result contains AC-2, interpret the classification result of the sample to be analyzed. It is AC-2. If the candidate classification result does not contain AC-2, then analyze whether the candidate classification result of the sample to be analyzed contains the cell classification morphology of AC-1. If the candidate classification result contains AC-1 , including AC-1 in the initial classification result of the sample to be analyzed, and according to a predetermined threshold, screen out the cell classification forms exceeding the predetermined threshold from other cell classification forms, as the initial classification result of the sample to be analyzed, On the other hand, if the classification candidate result does not contain AC-1, according to the predetermined threshold, the cell classification forms exceeding the predetermined threshold are selected from the cell classification forms as the initial classification result of the sample to be analyzed;

其中,該預定閥值係為一數值,可代表出現次數或出現機率,意即透過統計分析上之多數決模式篩選出重複率滿足該預定閥值之細胞分類形態,並將之納入該初分類結果,例如:該預定閥值為0.5,表示該分類候選結果中之細胞形態分類為出現機率大於或等於0.5者始能被納入初分類結果。The predetermined threshold is a numerical value, which can represent the number of occurrences or the probability of occurrence, that is, the cell classification forms whose repetition rate meets the predetermined threshold are screened out through the majority decision model in statistical analysis, and are included in the initial classification As a result, for example, the predetermined threshold value is 0.5, which means that the cell morphology in the classification candidate result can only be included in the preliminary classification result if the probability of occurrence is greater than or equal to 0.5.

步驟104-3:分析該初分類結果。Step 104-3: Analyze the preliminary classification result.

若該初分類結果僅包含單一細胞分類形態時,判讀該待析樣本之分類結果為初分類結果,亦即終判讀部採用初判讀部之結果,分類結果為單一細胞分類形態;If the preliminary classification result only includes single cell classification form, the classification result of the sample to be analyzed is the preliminary classification result, that is, the final interpretation part adopts the result of the preliminary interpretation part, and the classification result is the single cell classification form;

若該初分類結果為在不同影像中包含複數個細胞分類形態,則僅將出現次數大於或等於一預定值者納入分類結果,意即終判讀部會依據所設定之數值篩選出符合之細胞分類形態,而若所篩選出之細胞分類形態係為2種以上時,則分類結果係為混合形態,舉例來說,可將出現次數設定為大於或等於2。If the initial classification result contains multiple cell classification forms in different images, only those whose occurrence times are greater than or equal to a predetermined value will be included in the classification result, which means that the final interpretation unit will screen out the corresponding cell classification according to the set value. If there are more than two types of cell classification forms, the classification result is a mixed form, for example, the number of occurrences can be set to be greater than or equal to 2.

藉由本發明所揭抗細胞抗體之自動判讀方法係能夠直接由免疫染色影像之內容準確地判讀出其所對應之細胞分類形態,並且克服習知技術中無法準確判讀出混合形態或是專家等級之細胞分類形態之缺失,而透過該抗細胞抗體之自動判讀方法所提供之分類結果,係能夠提供臨床上做更進一步抗體檢驗或是疾病治療之參考,不需再仰賴大量人力進行影像之判讀。The automatic interpretation method of the anti-cell antibody disclosed in the present invention can directly determine the corresponding cell classification form directly from the content of the immunostaining image, and overcome the inability to accurately determine the mixed morphology or the expert level in the prior art. The lack of cell classification and morphology, and the classification results provided by the automatic interpretation method of anti-cell antibodies can provide clinical reference for further antibody testing or disease treatment, without relying on a lot of manpower for image interpretation.

又,必須要強調者,透過本發明所揭抗細胞抗體之自動判讀系統及其自動判讀方法,操作者僅需要提供待析樣品之ANA IIFA影像,而非以與特定自體免疫疾病相關之抗體進行染色後之影像作為判讀之輸入來源,換言之,本發明所揭抗細胞抗體之自動判讀系統及其自動判讀方法係大幅縮短檢測時間與檢測成本,更提高自動檢測之準確率。In addition, it must be emphasized that through the automatic interpretation system and automatic interpretation method of anti-cellular antibodies disclosed in the present invention, the operator only needs to provide the ANA IIFA image of the sample to be analyzed, rather than the antibody related to a specific autoimmune disease. The stained image is used as the input source for interpretation. In other words, the automatic interpretation system and automatic interpretation method of anti-cellular antibodies disclosed in the present invention greatly shorten the detection time and detection cost, and further improve the accuracy of automatic detection.

能更進一步說明本發明之技術特徵及其功效,以下將舉例並搭配圖表做詳細說明如後。To further illustrate the technical features and effects of the present invention, the following examples and diagrams will be used for detailed description as follows.

實例一:收集樣本及其ANA IIFA圖像Example 1: Collection of samples and their ANA IIFA images

自台灣台中榮民總醫院的NOVA View影像自動影像擷取設備自樣本收集到90109份具有ANA IIFA圖像(每個樣本會產出3-8個圖像),並若樣本及其圖像符合下列條件之任一,即將之排除:缺乏正式報告、週期性預先測試樣本、嚴重異常曝光的圖像,剩餘樣本為34982個。如下表4所示,18380個IIFA圖像被判讀為陰性(AC-0),而陰性之定義為細胞核、細胞質及分裂中期細胞都為陰性免疫螢光染色;其餘16602的ANA IIFA圖像(來自10641個患者)被判讀為非AC-0並會對應到1個以上之細胞形態分類;並且後續進行相關之抗體測試;其中,表4中之MSA為myositis specific antibody panel之縮寫。90,109 images with ANA IIFA (each sample will produce 3-8 images) were collected from the NOVA View image automatic image capture equipment of Taichung Veterans General Hospital, Taiwan, and if the sample and its images conform to Any of the following conditions will be excluded: lack of formal reports, periodic pre-test samples, severely abnormally exposed images, with 34,982 remaining samples. As shown in Table 4 below, 18,380 IIFA images were judged to be negative (AC-0), and negative was defined as negative immunofluorescence staining for the nucleus, cytoplasm, and metaphase cells; the remaining 16,602 ANA IIFA images (from 10641 patients) were judged to be non-AC-0 and corresponded to more than one cell morphology classification; and subsequent related antibody tests were performed; among them, MSA in Table 4 is the abbreviation of myositis specific antibody panel.

表4:ANA圖樣分類分佈 ICAP勝任等級分類 病患數量 (%) 樣本數量 (%) 用於機器學習的數量 實驗室提供的相關測試 臨床判斷接受後續測試之患者數量/陽性數量(%) 訓練 驗證 測試 核均質(AC-1) 6293 (24.3) 8717 (24.9) 21596 5398 3106 抗DsDNA抗體 2166/472 (21.8) 抗組蛋白抗體 115/30 (26.1) 核密集具有細斑點(AC-2) 247  (1) 401 (1.1) 981 244 95 著絲粒(AC-3) 545  (2.1) 910 (2.6) 2239 561 307 抗著絲粒抗體 304/293 (96.4) 核斑點(AC-4/AC-5) 10632 (41) 15078 (43.1) 37577 9396 5813 抗SSA/SSB抗體 5403/1547 (28.6) 抗Mi2、TIF NXP2、SAE1、 Ku、Ro52的自身抗體 (MSA panel) 1039/442 (42.5) 抗Sm/RNP抗體 245/144 (58.8) 離散核點(AC-6/AC-7) 446 (1.7) 755 (2.2) 1882 470 213 抗NXP2抗體 25/2 (8) 核仁(AC-8/AC-9/AC-10) 782 (3) 1022 (2.9) 2524 630 326 抗-PM-Scl 75/100 (MSA panel)或 Scl-70抗體 187/9 (26.2) 細胞質纖維(AC-15/AC-16/AC-17) 107 (0.4) 129 (0.4) 410 103 28 細胞質斑點(AC-18/AC-19/AC-20) 2005 (7.7) 2534 (7.2) 6380 1595 1122 抗PL-7、PL-12、Jo-1、 SRP、EJ、OJ、 MDA5、Ro52抗體 (MSA panel) 153/110 (71.9) 抗Jo-1抗體 90/13 (14.4) 抗核醣體-P抗體 26/10 (38.5) 細胞質網狀/AMA(AC-21) 264 (1) 380 (1.1) 980 245 105 抗粒線體抗體 89/53 (59.6) 抗粒線體-M2抗體 10/9 (90) Pola/Golgi-like(AC-22) 37 (0.1) 55 (0.2) 463 116 15 棒狀與環狀(AC-23) 44 (0.2) 54 (0.2) 635 159 18 AC-0 11373 (44.1) 16376 (47.1)         非AC-0 15299 (59.3) 18380 (52.9)           Table 4: ANA pattern classification distribution ICAP Competency Level Classification Number of patients (%) Number of samples(%) Quantity for Machine Learning Relevant tests provided by the laboratory Clinical judgment Number of patients receiving follow-up tests/number of positives (%) train verify test Nuclear Homogenization (AC-1) 6293 (24.3) 8717 (24.9) 21596 5398 3106 anti-DsDNA antibody 2166/472 (21.8) anti-histone antibody 115/30 (26.1) Nuclei dense with fine spots (AC-2) 247 (1) 401 (1.1) 981 244 95 none none Centromere (AC-3) 545 (2.1) 910 (2.6) 2239 561 307 anti-centromeric antibody 304/293 (96.4) Nuclear Speck (AC-4/AC-5) 10632 (41) 15078 (43.1) 37577 9396 5813 Anti-SSA/SSB antibody 5403/1547 (28.6) Autoantibodies against Mi2, TIF NXP2, SAE1, Ku, Ro52 (MSA panel) 1039/442 (42.5) Anti-Sm/RNP antibody 245/144 (58.8) Discrete core points (AC-6/AC-7) 446 (1.7) 755 (2.2) 1882 470 213 Anti-NXP2 antibody 25/2 (8) Nucleolus (AC-8/AC-9/AC-10) 782 (3) 1022 (2.9) 2524 630 326 Anti-PM-Scl 75/100 (MSA panel) or Scl-70 antibody 187/9 (26.2) Cytoplasmic fibers (AC-15/AC-16/AC-17) 107 (0.4) 129 (0.4) 410 103 28 none none Cytoplasmic spots (AC-18/AC-19/AC-20) 2005 (7.7) 2534 (7.2) 6380 1595 1122 Anti-PL-7, PL-12, Jo-1, SRP, EJ, OJ, MDA5, Ro52 antibodies (MSA panel) 153/110 (71.9) Anti-Jo-1 antibody 90/13 (14.4) anti-ribosome-P antibody 26/10 (38.5) Cytoplasmic reticulum/AMA (AC-21) 264 (1) 380 (1.1) 980 245 105 anti-mitochondrial antibody 89/53 (59.6) Anti-mitochondrial-M2 antibody 10/9 (90) Pola/Golgi-like (AC-22) 37 (0.1) 55 (0.2) 463 116 15 none none Rod and Ring (AC-23) 44 (0.2) 54 (0.2) 635 159 18 none none AC-0 11373 (44.1) 16376 (47.1) Not AC-0 15299 (59.3) 18380 (52.9)

實例二:影像處理(一)Example 2: Image Processing (1)

由於實例一中各細胞形態分類之數量不平均而可能造成機器學習結果不佳,再收集部分具有細胞質纖維、細胞質網狀/AMA或細胞質為Polar/Golgi-like圖樣等陽性表現之患者血清,做更進一步之ANA測試,以得到121個細胞質纖維陽性之圖像、74個細胞質網狀/AMA陽性之圖像,及406個細胞質為Pola/Golgi-like之圖像,並且,透過亮度增減技術來擴增呈桿狀與環狀之細胞態樣的圖樣,得到624個增強後之圖像;上述圖樣仍投入輸入端,作為機器學習之訓練數據,如上表4所示。Due to the uneven number of morphological classifications of cells in Example 1, the results of machine learning may be poor. Then, some patients' sera with positive manifestations such as cytoplasmic fibers, cytoplasmic reticulum/AMA or cytoplasmic polar/Golgi-like patterns were collected. The ANA test was further carried out to obtain 121 cytoplasmic fiber-positive images, 74 cytoplasmic reticulum/AMA-positive images, and 406 cytoplasmic Pola/Golgi-like images, and through the brightness increase and decrease technology To amplify the patterns of rod-shaped and ring-shaped cells, 624 enhanced images were obtained; the above-mentioned patterns were still input to the input end as training data for machine learning, as shown in Table 4 above.

實例三:影像處理(二)Example 3: Image Processing (2)

由於所有HEp-2 細胞ANA IIFA 圖像資訊都只存在綠色通道(green channel),因此需移除ANA IIFA圖像中藍色及紅色通道,以避免雜訊,並且,更得對各ANA IIFA圖像進行影像預處理透過像素調整方法,適當地增強影像之強度對比,以使強度值能夠均一化至0~1之間的比例,其中,強度調整方法如下:Since all the ANA IIFA image information of HEp-2 cells has only the green channel, the blue and red channels in the ANA IIFA images need to be removed to avoid noise. Perform image preprocessing through pixel adjustment method to appropriately enhance the intensity contrast of the image, so that the intensity value can be normalized to a ratio between 0 and 1, wherein the intensity adjustment method is as follows:

輸入圖像增加值=(輸入圖像-輸入圖像最小強度值)/(輸入圖像最大強度值-輸入圖像最小強度值)Input image increase value = (input image - input image minimum intensity value) / (input image maximum intensity value - input image minimum intensity value)

實例四:機器學習之訓練規則Example 4: Training rules for machine learning

由於根據ICAP之分類規則,ANA細胞形態分類必須要同時考慮到分裂中期細胞、間期細胞(interphase cell),因此,輸入圖像是基於HEp-2細胞影像之圖像等級(specimen-level 或稱 image-level),而非基於HEp-2細胞影像之細胞等級(cell-level)。According to the classification rules of ICAP, the morphological classification of ANA cells must take into account metaphase cells and interphase cells at the same time. Therefore, the input image is based on the image level of HEp-2 cell images (specimen-level or image-level) rather than cell-level based on HEp-2 cell images.

以本實例來說,所有的圖樣都依據80:20之比例進行訓練及驗證,並調整尺寸為299 X 299像素。於GPU機器學習環境(NVIDIA TITAN V, 12GB RAM)下進行30期(epoch)之訓練,最小批量為30。For this example, all patterns are trained and validated according to the 80:20 ratio and resized to 299 X 299 pixels. 30 epochs (epoch) of training were performed under the GPU machine learning environment (NVIDIA TITAN V, 12GB RAM), with a minimum batch size of 30.

實例五:機器學習之判讀規則Example 5: Interpretation rules of machine learning

由於ANA檢查針對每個樣品至少會有3張免疫螢光影像,故需結合所有判讀結果,並且以多數決之方式來決定最終之判讀結果,因此,對於每個HEp-2細胞圖像,藉由預訓練模型在11種可能的細胞形態分類上產出概率分佈,並選擇概率大於等於0.5之細胞形態分類作為初判讀圖像預測結果;於每個樣本之圖像中,採取至少被兩個HEp-2細胞圖像所得圖像預測結果支持的細胞形態分布作為最終判讀結果;惟,初判讀例外情形如下:Since the ANA test will have at least 3 immunofluorescence images for each sample, all the interpretation results need to be combined and the final interpretation result will be determined by a majority vote. Therefore, for each HEp-2 cell image, use The pre-trained model produces probability distributions on 11 possible cell shape classifications, and selects cell shape classifications with a probability greater than or equal to 0.5 as the initial interpretation image prediction result; in each sample image, at least two The cell morphology distribution supported by the image prediction results obtained from the HEp-2 cell image is used as the final interpretation result; however, the exceptions to the initial interpretation are as follows:

1.判斷是否出現核質均勻染(AC-1)之情形的主要關鍵在於分裂中期細胞,但是典型的分裂中期細胞可能僅會出現在各樣本的所有影像中之一張,所以只要其中一張圖像預測結果含有核質均勻染陽性(即AC-1),則最終之判讀就將核質均勻染陽性(AC-1)納入終判讀結果;1. The main key to judging whether there is uniform nuclear and cytoplasmic staining (AC-1) lies in metaphase cells, but typical metaphase cells may only appear in one of all the images of each sample, so only one of them If the image prediction result contains nucleocytoplasmic uniform staining positive (ie AC-1), then the final interpretation will include nucleocytoplasmic uniform staining positive (AC-1) in the final interpretation result;

2.AC-2理論上是不會和AC-1及/或AC-4共存,所以當圖像預測結果是AC-2時,則自動忽略AC-1及AC-4。2. In theory, AC-2 will not coexist with AC-1 and/or AC-4, so when the image prediction result is AC-2, AC-1 and AC-4 are automatically ignored.

舉例來說,請參圖8,於本例中,初判讀部的閥值設為大於或等於0.5,終判讀部的閥值設為次數為2或2以上;根據此設定,初判讀部先依據所設定之閥值自各免疫螢光影像之分類候選結果中進行篩選並且同時分析是否有上述初判讀例外情形;由於本例中沒有初判讀例外情形,故初判讀部留下AC-4(2次)、AC-19(2次)、AC-6(1次)之初分類結果,而後終判讀部再依據所設定之閥值篩選出分類結果,即為AC-4及AC-19之混合形態。For example, please refer to FIG. 8. In this example, the threshold value of the initial judgment part is set to be greater than or equal to 0.5, and the threshold value of the final judgment part is set to be 2 or more; According to the set threshold, the classification candidate results of each immunofluorescence image are screened, and at the same time, it is analyzed whether there are the above-mentioned exceptions to the initial interpretation; since there are no exceptions to the initial interpretation in this case, the initial interpretation department leaves AC-4 (2). times), AC-19 (2 times), and AC-6 (1 time), the initial classification results, and then the final interpretation department filters out the classification results according to the set threshold, which is a mixture of AC-4 and AC-19 form.

又請參圖9,於該例中,初判讀部與終判讀部的閥值設定同於上例,然由於影像1及影像2之分類候選結果中含有AC-2之細胞分類形態,此即為初判讀例外情形,因此,於影像1及影像2之初分類結果係會留下AC-2,而影像3中因為沒有出現AC-2,所以初分類結果留下AC-1及AC-4;基於AC-2於初分類結果中之出現次數等於2,所以終判讀部僅留下AC-2作為分類結果。Please refer to FIG. 9 again. In this example, the threshold settings of the initial interpretation part and the final interpretation part are the same as those in the previous example. However, since the classification candidate results of image 1 and image 2 contain the cell classification form of AC-2, this is This is an exception to the initial interpretation. Therefore, AC-2 is left in the initial classification results of Image 1 and Image 2, and AC-1 and AC-4 are left in the initial classification results because AC-2 does not appear in Image 3. ; Based on the number of occurrences of AC-2 in the initial classification result is equal to 2, so the final interpretation part only leaves AC-2 as the classification result.

請再參圖10,於該例中,初判讀部與終判讀部的閥值設定同於上例;而雖然初分類結果中AC-4出現3次、AC-1出現1次,然基於前述初判讀例外情形之規則,只要初分類結果中有出現AC-1,就應將AC-1納入分類結果中,不用考慮AC-1之出現次數,故於本例中之分類結果為AC-1及AC-4之混合形態。Please refer to FIG. 10 again. In this example, the threshold settings of the initial judgment part and the final judgment part are the same as the above example; and although AC-4 appears 3 times and AC-1 appears 1 time in the initial classification result, based on the aforementioned As long as AC-1 appears in the initial classification result, AC-1 should be included in the classification result, regardless of the number of occurrences of AC-1, so the classification result in this example is AC-1. And the hybrid form of AC-4.

實例六:分類判讀結果之評估方式Example 6: Evaluation Method of Classification Interpretation Results

透過精確度(陽性預測正確的比例)、靈敏度(recall,正確分類陽性的比例及F1分數(精確度和召回率的加權平均表現),其分別以下列算式運算所得:Through precision (the proportion of positive predictions that are correct), sensitivity (recall, the proportion of correctly classified positives), and F1 score (the weighted average performance of precision and recall), they are calculated as follows:

精確度=真陽性/(真陽性+偽陽性)Precision = true positives / (true positives + false positives)

靈敏度=真陽性/(真陽性+偽陰性)Sensitivity = true positives / (true positives + false negatives)

F1分數=(2 X精準度 X 靈敏度)/(精準度 + 靈敏度)F1 Score = (2 X Accuracy X Sensitivity) / (Accuracy + Sensitivity)

此外,Kappa值(Cohen’s kappa)亦能作為評估分類結果是否一致的指標,其中:In addition, the Kappa value (Cohen's kappa) can also be used as an indicator to evaluate whether the classification results are consistent, among which:

Kappa值=(P 0-P C)/(1-P CKappa value = (P 0 -P C )/(1-P C )

P 0為觀測一致性(observed agreement),兩種測量結果一致的百分比; P 0 is the observed agreement, the percentage of two measurement results that are consistent;

P C為期望一致性(chance agreement),兩種測量結果預期相同的百分比。 PC is the chance agreement, the percentage that two measurements are expected to be the same.

實例七:以比較不同機器學習模型進行演算之結果Example 7: Comparing the Calculation Results of Different Machine Learning Models

藉由測試數據1評估不同預訓練模型之效果,其中,該測試數據1(如圖3)包含1985個樣本及其所產生之6195個圖像,結果如表5所示。The effects of different pre-training models are evaluated by test data 1, wherein the test data 1 (as shown in Figure 3) contains 1985 samples and 6195 images generated by them. The results are shown in Table 5.

由表5之結果可知,以InceptionResNetV2模型進行演算可以得到最高F1分數(0.86)和最高kappa值(0.82),是以,將通過轉移學習技術(transfer learning technique)採取InceptionResNetV2模型作為機器學習之演算法,演算架構如圖4所示。From the results in Table 5, it can be seen that the highest F1 score (0.86) and the highest kappa value (0.82) can be obtained with the InceptionResNetV2 model. Therefore, the InceptionResNetV2 model will be used as the machine learning algorithm through the transfer learning technique. , the calculus architecture is shown in Figure 4.

將測試數據1以InceptionResNetV2模型進行演算,而對於不同細胞分類形態之精準度、靈敏度、F1分數及Kappa值係如表6所示,其中,Kappa值係顯示InceptionResNetV2模型預測結果與具有經驗醫檢師判讀結果間之一致性。The test data 1 is calculated by the InceptionResNetV2 model, and the accuracy, sensitivity, F1 score and Kappa value of different cell classification forms are shown in Table 6. Among them, the Kappa value shows that the prediction results of the InceptionResNetV2 model are different from those of experienced medical examiners. Consistency between interpretation results.

由表6之結果顯示,精準度係介於0.73~1.00之間,平均為0.93;靈敏度係介於0.64~1.00之間,平均為0.81;F1分數係係介於0.72~1.00之間,平均為0.86。F1分數最高之三種細胞分類形態之圖像特徵為棒狀與環狀、核斑點及著絲粒,而F1分數最低之四種細胞分類形態之圖像特徵為細胞質斑點、核仁、離散核點、細胞質纖維。再者,各細胞形態分類之Kappa值在0.67到1.00,平均為0.82,表示以機器學習所得之分類判斷標準進行判讀之結果與人工判讀結果間達成幾乎完美的一致性。The results in Table 6 show that the accuracy is between 0.73 and 1.00, with an average of 0.93; the sensitivity is between 0.64 and 1.00, with an average of 0.81; the F1 score is between 0.72 and 1.00, with an average of 0.81. 0.86. The image features of the three cell types with the highest F1 scores are rods and rings, nuclear speckles and centromeres, while the image features of the four cell types with the lowest F1 scores are cytoplasmic speckles, nucleoli, and discrete nuclear dots. , cytoplasmic fibers. Furthermore, the Kappa value of each cell morphological classification ranges from 0.67 to 1.00, with an average of 0.82, indicating that the results of interpretation based on the classification criteria obtained by machine learning and the results of manual interpretation have achieved almost perfect consistency.

換言之,由上述結果可以證實本發明所揭抗細胞抗體之自動判讀系統及其自動判讀方法係能夠準確地判讀出ANA IIFA影像之細胞形態分類,以達到降低人工判讀之成本並提升判讀效率。In other words, from the above results, it can be confirmed that the automatic interpretation system and automatic interpretation method of anti-cellular antibodies disclosed in the present invention can accurately interpret the cell morphology classification of ANA IIFA images, so as to reduce the cost of manual interpretation and improve the interpretation efficiency.

表5:以不同預訓練模型進行演算後之F1分數及Kappa值 預訓練模型 F1 分數 Kappa值 InceptionResNetV2 0.86 0.82 MobileNetV2 0.81 0.76 Xception 0.78 0.74 VGG19 0.78 0.73 ResNet50V2 0.73 0.68 DenseNet121 0.68 0.63 Table 5: F1 scores and Kappa values after calculation with different pretrained models pretrained model F1 Score Kappa value InceptionResNetV2 0.86 0.82 MobileNetV2 0.81 0.76 Xception 0.78 0.74 VGG19 0.78 0.73 ResNet50V2 0.73 0.68 DenseNet121 0.68 0.63

表6:測試數據1中各細胞形態分類以InceptionResNetV2進行演算之結果   精準度 靈敏度 F1 分數 Kappa值 核均質 0.92 0.87 0.89 0.79 核密集具有細斑點 0.88 0.79 0.83 0.83 著絲粒 1.00 0.88 0.93 0.93 核斑點 0.98 0.99 0.99 0.74 離散核點 0.94 0.70 0.80 0.79 核仁 1.00 0.64 0.78 0.77 細胞質纖維 0.73 0.89 0.80 0.80 細胞質斑點 0.82 0.65 0.72 0.67 細胞質網狀/AMA 0.92 0.73 0.81 0.81 Polar/Golgi-like 1.00 0.80 0.89 0.89 棒狀與環狀 1.00 1.00 1.00 1.00 Table 6: Calculation results of each cell morphology classification in test data 1 using InceptionResNetV2 Accuracy Sensitivity F1 Score Kappa value nuclear homogeneity 0.92 0.87 0.89 0.79 Nuclei are dense with fine spots 0.88 0.79 0.83 0.83 Centromere 1.00 0.88 0.93 0.93 nuclear speck 0.98 0.99 0.99 0.74 discrete core points 0.94 0.70 0.80 0.79 Nucleolus 1.00 0.64 0.78 0.77 cytoplasmic fibers 0.73 0.89 0.80 0.80 cytoplasmic spots 0.82 0.65 0.72 0.67 Cytoplasmic reticulum/AMA 0.92 0.73 0.81 0.81 Polar/Golgi-like 1.00 0.80 0.89 0.89 rod and ring 1.00 1.00 1.00 1.00

實例八:一致性測試Example 8: Conformance Test

隨機選擇175個樣本所產生之544個圖像,作為測試數據2,並分別將5個經驗豐富醫檢師人工判讀之結果、2個初級醫檢師人工判讀之結果和以InceptionResNetV2模型進行判讀之結果兩兩相比,分析彼此間之一致性,結果如圖5至圖7所示。544 images generated from 175 samples were randomly selected as test data 2, and the results of manual interpretation by 5 experienced medical examiners, the results of manual interpretation by 2 junior medical examiners, and the results of interpretation by the InceptionResNetV2 model were respectively used. The results were compared in pairs, and the consistency between them was analyzed. The results are shown in Figures 5 to 7.

由圖5至圖7之結果係顯示,5位經驗豐富之醫檢師對11種細胞形態分類進行判讀所得結果的平均一致性為0.849,代表幾乎完美的一致性;而5位經驗豐富之醫檢師與2位初級醫檢師所得之判讀結果的平均一致性為0.528,代表為中等一致性;而以本發明所揭抗細胞抗體之自動判讀方法,透過機器學習(如InceptionResNetV2演算法)進行判讀所得之結果與5位有豐富經驗醫檢師所得之判讀結果間的一致性為0.844,代表彼此間呈現幾乎完美的一致性。The results from Figure 5 to Figure 7 show that the average consistency of the results obtained by 5 experienced medical examiners in the interpretation of 11 cell morphological classifications is 0.849, representing almost perfect consistency; The average agreement of the interpretation results obtained by the examiner and 2 junior medical examiners was 0.528, representing moderate agreement; and the automatic interpretation method of anti-cellular antibodies disclosed in the present invention was carried out through machine learning (such as the InceptionResNetV2 algorithm). The consistency between the interpretation results and the interpretation results obtained by 5 experienced medical examiners was 0.844, which represented an almost perfect consistency with each other.

由上述結果證實,本發明所揭抗細胞抗體之自動判讀系統及其自動判讀方法判讀ANA IIFA影像之正確度係明顯高於初級人員,意即透過本發明所揭抗細胞抗體之自動判讀系統及其自動判讀方法進行ANA IIFA影像判讀,不僅能夠降低人工判讀因人為因素所造成之錯誤率,並能夠判斷出多種細胞形態分類,包含混合形態及專家等級之細胞形態分類,不僅能夠節省人力及時間成本,更能達到準確且快速地判讀ANA IIFA影像之功效,以達到輔助臨床上對於自體免疫疾病之判斷與治療之功效。The above results confirm that the accuracy of the automatic interpretation system and the automatic interpretation method of the anti-cellular antibody disclosed in the present invention in interpreting ANA IIFA images is significantly higher than that of the junior staff, which means that the automatic interpretation system of the anti-cellular antibody disclosed in the present invention and Its automatic interpretation method for ANA IIFA image interpretation can not only reduce the error rate caused by human factors in manual interpretation, but also can determine a variety of cell morphological classifications, including mixed morphological and expert-level cell morphological classification, which not only saves manpower and time Cost, more accurate and rapid interpretation of ANA IIFA images, in order to achieve the effect of assisting clinical judgment and treatment of autoimmune diseases.

(10):抗細胞抗體之自動判讀系統 (20):資料模組 (30):輸入模組 (31):影像成像單元 (32):影像調整單元 (40):處理模組 (41):運算單元 (42):辨識單元 (43):分析單元 (431):初判讀部 (432):終判讀部 (101):輸入一待析樣本 (102):處理該待析樣本,得到一待析參數 (103):提供一細胞形態分類標準 (104):依據該細胞形態分類標準,對該待析參數進行分析處理,得到該待析樣本對應之細胞形態分類 (104-1):依序判斷該待析樣本中之細胞核、細胞質及分裂中期細胞之染色情形 (104-2):分析該分類候選結果 (104-3):分析該初分類結果 (10): Automatic interpretation system of anti-cell antibodies (20):Data module (30): Input module (31): Image imaging unit (32): Image adjustment unit (40):processing module (41): operation unit (42): identification unit (43): Analysis Unit (431): Preliminary Interpretation Department (432): Final Interpretation Department (101): Input a sample to be analyzed (102): process the sample to be analyzed to obtain a parameter to be analyzed (103): provide a cell morphology classification standard (104): according to the cell morphology classification standard, analyze and process the parameters to be analyzed, and obtain the cell morphology classification corresponding to the sample to be analyzed (104-1): Sequentially determine the staining status of the nucleus, cytoplasm and metaphase cells in the sample to be analyzed (104-2): Analyze the classification candidate results (104-3): Analyze the preliminary classification results

圖1係為本發明第一實施例之示意圖。 圖2係為本發明第二實施例之流程圖。 圖3係為本發明實例中所述機器學習模型架構圖。 圖4係為本發明實例中所述進行判讀之流程圖。 圖5係為分析以不同經驗豐富醫檢師所得判讀結果間的一致性,其中,A1至A5分別代表5位不同經驗豐富醫檢師,而表格內之數字代表該些醫檢師之間對於各種形態判讀一致性之結果,並Kappa值小於0代表一致性不佳、0-0.2代表一致性很低、0.21-0.40代表一致性少、0.41-0.60代表一致性中、0.61-0.80代表一致性強、0.81-1代表將近完美的一致性。 圖6係為分析以經驗豐富醫檢師與以初級醫檢師所得判讀結果間的一致性,其中,A1至A5分別代表5位不同經驗豐富醫檢師,F1至F2分別代表2位初級醫檢師,表格內數字代表不同經驗豐富醫檢師與初級醫檢師之間對於各種形態判讀一致性之結果。 圖7係為分析以經驗豐富醫檢師與以自動判讀系統所得判讀結果間的一致性,其中,A1至A5分別代表5位不同經驗豐富醫檢師,AI代表自動判讀系統,表格內數字代表不同經驗豐富醫檢師與自動判讀系統之間對於各種形態判讀一致性之結果。 圖8係為本發明所揭機器學習判讀規則之流程示意圖(一)。 圖9係為本發明所揭機器學習判讀規則之流程示意圖(二)。 圖10係為本發明所揭機器學習判讀規則之流程示意圖(三)。 FIG. 1 is a schematic diagram of a first embodiment of the present invention. FIG. 2 is a flowchart of a second embodiment of the present invention. FIG. 3 is an architecture diagram of the machine learning model described in the example of the present invention. FIG. 4 is a flow chart of the interpretation described in the example of the present invention. Figure 5 is an analysis of the consistency between the interpretation results obtained by different experienced medical examiners, in which, A1 to A5 represent 5 different experienced medical examiners respectively, and the numbers in the table represent the differences among these medical examiners. The results of the interpretation consistency of various morphologies, and the Kappa value less than 0 means poor consistency, 0-0.2 means very low consistency, 0.21-0.40 means little consistency, 0.41-0.60 means consistency, 0.61-0.80 means consistency Strong, 0.81-1 represents near-perfect consistency. Figure 6 is an analysis of the consistency between the interpretation results obtained by experienced medical examiners and junior medical examiners. Among them, A1 to A5 represent 5 different experienced medical examiners, and F1 to F2 represent 2 junior medical examiners respectively. Examiners, the numbers in the table represent the results of the consistency of interpretation of various forms between different experienced medical examiners and junior medical examiners. Figure 7 is an analysis of the consistency between the interpretation results obtained by experienced medical examiners and the automatic interpretation system. Among them, A1 to A5 represent 5 different experienced medical examiners, AI represents the automatic interpretation system, and the numbers in the table represent Interpretation consistency results for various modalities between different experienced medical examiners and automated interpretation systems. FIG. 8 is a schematic flowchart (1) of a machine learning interpretation rule disclosed in the present invention. FIG. 9 is a schematic flowchart (2) of a machine learning interpretation rule disclosed in the present invention. FIG. 10 is a schematic flowchart (3) of the machine learning interpretation rules disclosed in the present invention.

Claims (10)

一種抗細胞抗體之自動判讀系統,係包含有: 一資料模組,存放有複數樣本免疫染色影像之細胞形態分類及其分類特徵,其中,該分類特徵係包含有細胞質、細胞核及分裂中期細胞之有無、數量、比例、亮度、分佈、外型,及彼此間之關聯性等; 一輸入模組,自一待測樣本中取得至少一待析免疫染色影像; 一處理模組,具有一運算單元,接收來自該資料模組內之該些樣本免疫染色影像之細胞形態分類及其分類特徵,經運算而建構出一組分類標準,一辨識單元,接收該待析免疫染色影像並進行辨識處理,得到一辨識結果,包含該待析免疫染色影像中之細胞質、細胞核及/或分裂中期細胞之有無、外型、亮度、分佈,及彼此間之關聯性等參數,一分析單元,依據該分類標準分析處理該辨識結果,得到該待析免疫染色影像對應細胞形態分類之一判讀結果。 An automatic interpretation system for anti-cell antibodies, comprising: 1. A data module, which stores the cell morphology classification and classification features of immunostaining images of multiple samples, wherein the classification features include the presence or absence, number, proportion, brightness, distribution, and appearance of cytoplasm, nuclei, and metaphase cells; and their relationship with each other; an input module for obtaining at least one immunostaining image to be analyzed from a sample to be tested; A processing module has an operation unit, which receives the cell morphology classification and classification characteristics of the immunostained images of the samples from the data module, and constructs a set of classification standards through operation, and an identification unit receives the to-be-to-be-stained images. Analyze the immunostaining image and perform identification processing to obtain an identification result, including the presence or absence, appearance, brightness, distribution of cytoplasm, nucleus and/or metaphase cells in the immunostained image to be analyzed, and their correlation with each other and other parameters , an analysis unit that analyzes and processes the identification result according to the classification standard, and obtains an interpretation result of the cell morphology classification corresponding to the immunostaining image to be analyzed. 如請求項1所述抗細胞抗體之自動判讀系統,其中,該輸入模組係包含有一影像成像單元,用以自該待測樣本中取得一預定數量之待析免疫染色影像。The automatic interpretation system for anti-cellular antibodies according to claim 1, wherein the input module includes an image imaging unit for obtaining a predetermined number of immunostaining images to be analyzed from the sample to be tested. 如請求項2所述抗細胞抗體之自動判讀系統,其中,該分析單元更包含有一初判讀部及一終判讀部; 該初判讀部係依據該分類標準分析該辨識結果,得到一初判結果;該終判讀部係依據一預定閥值或是多數決演算法分析該初判結果,產出該判讀結果。 The automatic interpretation system for anti-cellular antibodies according to claim 2, wherein the analysis unit further comprises a preliminary interpretation part and a final interpretation part; The preliminary judgment section analyzes the identification result according to the classification standard to obtain a preliminary judgment result; the final judgment section analyzes the preliminary judgment result according to a predetermined threshold or a majority decision algorithm, and outputs the judgment result. 一種抗細胞抗體之自動判讀方法,其包含有下列步驟: 輸入一待析樣本,得到該待析樣本之至少一影像; 處理該影像,得到一待析參數,其中,該待析參數包含有細胞質、細胞核及/或分裂中期細胞之染色結果、外型、亮度、分佈,及彼此間之關聯性等; 提供一細胞形態分類標準,其係由複數已知免疫染色影像之細胞形態分類及其分類特徵經運算處理而得者; 依據該細胞形態分類標準,對該待析樣本之影像得到之該待析參數進行分析處理,得到該待析樣本對應之細胞形態分類。 An automatic interpretation method for anti-cell antibodies, which comprises the following steps: inputting a sample to be analyzed to obtain at least one image of the sample to be analyzed; processing the image to obtain a parameter to be analyzed, wherein the parameter to be analyzed includes the staining result, appearance, brightness, distribution, and correlation between cytoplasm, nucleus and/or metaphase cells; Provide a cell morphological classification standard, which is obtained by calculating the cell morphological classification and classification characteristics of a plurality of known immunostaining images; According to the cell shape classification standard, the parameters to be analyzed obtained from the image of the sample to be analyzed are analyzed and processed to obtain the cell shape classification corresponding to the sample to be analyzed. 如請求項4所述抗細胞抗體之自動判讀方法,其中,該影像係為以一預定抗體進行免疫細胞染色之影像。The automatic interpretation method for anti-cell antibodies according to claim 4, wherein the image is an image of immune cells stained with a predetermined antibody. 如請求項4所述抗細胞抗體之自動判讀方法,其中,該些已知免疫細胞染色影像於運算處理前係進行影像擴增處理。The method for automatic interpretation of anti-cell antibodies according to claim 4, wherein the known immune cell staining images are subjected to image amplification processing before the arithmetic processing. 如請求項4所述抗細胞抗體之自動判讀方法,其中,該影像之數量至少為3。The automatic interpretation method for anti-cellular antibodies according to claim 4, wherein the number of the images is at least 3. 如請求項7所述抗細胞抗體之自動判讀方法,其中,步驟d中係更包含下列步驟: 步驟d1:根據各該影像之染色結果判斷該待析參數中之細胞核、細胞質及分裂中期細胞的有無,若為無,則判斷該待析樣本係為無反應(Non-reactive,AC-0),若為有,則比對該細胞形態分類標準而得到一分類候選結果; 步驟d2:分析該分類候選結果,其中: 當該分類候選結果僅包含單一細胞分類形態時,判讀該待析樣本之分類結果為該分類候選結果; 當該分類候選結果係為至少一影像中分別包含複數細胞分類形態,則先分析該些影像之該分類候選結果中是否包含有AC1、AC-2及/或AC-4之細胞形態分類,若有AC-2、及AC-1及/或AC-4,則需排除AC-1及/AC-4,將AC-2列入初分類結果,若無AC-2,但有AC-1,將AC-1納入該待析樣本之初分類結果,並且依據一預定閥值,自其他細胞分類形態中篩選出超出該預定閥值之細胞分類形態,作為該待析樣本之初分類結果,若無AC-2及AC-1,依據該預定閥值,自該些細胞分類形態中篩選出符合該預定閥值之細胞分類形態,作為該待析樣本之初分類結果; 步驟d3:分析該初分類結果,其中,若該初分類結果僅包含單一細胞分類形態時,判讀該待析樣本之分類結果為初分類結果;而當該初分類結果包含複數個細胞分類形態時,則需依據一預定條件分析是否符合細胞形態分類中之混合形態,其中,該預定條件包含有若初分類結果中含有AC-1,AC-1應納入分類結果,並其他初分類結果中之細胞分類形態應出現一預定次數者始能納入分類結果。 The automatic interpretation method of the anti-cellular antibody according to claim 7, wherein, in step d, the following steps are further included: Step d1: Determine the presence or absence of nucleus, cytoplasm and metaphase cells in the parameters to be analyzed according to the staining results of each image, if not, then determine that the sample to be analyzed is non-reactive (Non-reactive, AC-0) , if yes, compare the cell morphology classification criteria to obtain a classification candidate result; Step d2: analyze the classification candidate results, wherein: When the classification candidate result contains only a single cell classification form, interpret the classification result of the sample to be analyzed as the classification candidate result; When the classification candidate result is that at least one image respectively contains a plurality of cell classification forms, first analyze whether the classification candidate results of the images include the cell shape classification of AC1, AC-2 and/or AC-4. If there is AC-2, and AC-1 and/or AC-4, then AC-1 and /AC-4 need to be excluded, and AC-2 should be included in the preliminary classification result. If there is no AC-2, but there is AC-1, AC-1 is included in the initial classification result of the sample to be analyzed, and according to a predetermined threshold, the cell classification forms exceeding the predetermined threshold are selected from other cell classification forms as the initial classification result of the sample to be analyzed. If Without AC-2 and AC-1, according to the predetermined threshold, screen out the cell classification forms that meet the predetermined threshold from the cell classification forms, as the initial classification result of the sample to be analyzed; Step d3: analyze the preliminary classification result, wherein, if the preliminary classification result only includes a single cell classification form, interpret the classification result of the sample to be analyzed as the preliminary classification result; and when the preliminary classification result includes a plurality of cell classification forms , it is necessary to analyze whether it conforms to the mixed morphology in the cell morphology classification according to a predetermined condition, wherein the predetermined condition includes that if the initial classification result contains AC-1, AC-1 should be included in the classification result, and other initial classification results. Cell classification patterns should appear a predetermined number of times before they can be included in the classification results. 如請求項8所述抗細胞抗體之自動判讀方法,其中,該預定閥值係為細胞分類形態出現機率。The method for automatically interpreting anti-cell antibodies according to claim 8, wherein the predetermined threshold is the occurrence probability of cell classification morphology. 如請求項8所述細胞抗體之自動判讀方法,其中,該預定閥值係設為大於或等於0.5,並該預定次數係設為大於或等於2。The method for automatic interpretation of cellular antibodies according to claim 8, wherein the predetermined threshold is set to be greater than or equal to 0.5, and the predetermined number of times is set to be greater than or equal to 2.
TW109146569A 2020-12-28 2020-12-28 Automatic interpretation system and automatic interpretation method of anti-cell antibody TWI773057B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
TW109146569A TWI773057B (en) 2020-12-28 2020-12-28 Automatic interpretation system and automatic interpretation method of anti-cell antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TW109146569A TWI773057B (en) 2020-12-28 2020-12-28 Automatic interpretation system and automatic interpretation method of anti-cell antibody

Publications (2)

Publication Number Publication Date
TWI773057B TWI773057B (en) 2022-08-01
TW202229862A true TW202229862A (en) 2022-08-01

Family

ID=83782592

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109146569A TWI773057B (en) 2020-12-28 2020-12-28 Automatic interpretation system and automatic interpretation method of anti-cell antibody

Country Status (1)

Country Link
TW (1) TWI773057B (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019020556A1 (en) * 2017-07-24 2019-01-31 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
TWI705414B (en) * 2018-05-29 2020-09-21 長庚醫療財團法人林口長庚紀念醫院 Classification system and classification method of autoantibody immunofluorescence image
US20210293814A1 (en) * 2019-10-25 2021-09-23 Board Of Regents, The University Of Texas System Systems and methods for spectral imaging characterization of macrophages for use in personalization of targeted therapies to prevent fibrosis development in patients with chronic liver disease

Also Published As

Publication number Publication date
TWI773057B (en) 2022-08-01

Similar Documents

Publication Publication Date Title
US11151716B2 (en) Methods and systems for assessing cell morphology
US10083340B2 (en) Automated cell segmentation quality control
US8417015B2 (en) Methods and system for validating sample images for quantitative immunoassays
WO2012041333A1 (en) Automated imaging, detection and grading of objects in cytological samples
Bhagavatula et al. Automatic identification and delineation of germ layer components in H&E stained images of teratomas derived from human and nonhuman primate embryonic stem cells
Zhu et al. The identification of white fertile eggs prior to incubation based on machine vision and least square support vector machine
CN112990015B (en) Automatic identification method and device for lesion cells and electronic equipment
CN111815614B (en) Parasite detection method and system based on artificial intelligence and terminal equipment
JPH08504522A (en) Method and apparatus for identifying objects using a regular sequence of boundary pixel parameters
Lovell et al. International contest on pattern recognition techniques for indirect immunofluorescence images analysis
dos Santos et al. Automated nuclei segmentation on dysplastic oral tissues using cnn
CN116542978A (en) Quality detection method and device for FISH probe
Elbischger et al. Algorithmic framework for HEp-2 fluorescence pattern classification to aid auto-immune diseases diagnosis
CN114038507A (en) Prediction method, training method of prediction model and related device
CN107735838A (en) It is used for the abnormality detection of medical sample under a variety of settings
TWI773057B (en) Automatic interpretation system and automatic interpretation method of anti-cell antibody
CN109633143B (en) System and method for detecting bone marrow microcirculation environment of patient after hematopoietic stem cell transplantation
JPH10185911A (en) Device for analyzing cell and method therefor
Kotyk et al. Detection of dead stained microscopic cells based on color intensity and contrast
CN113178228A (en) Cell analysis method based on nuclear DNA analysis, computer device, and storage medium
Tan et al. Automated Classification Map Generation of Prostate Cancer using Deep Learning
Schnorrenberg Comparison of manual and computer-aided breast cancer biopsy grading
Maza et al. NMJ-Analyser: high-throughput morphological screening of neuromuscular junctions identifies subtle changes in mouse neuromuscular disease models
Villegas-Jimenez et al. Causal Scoring Medical Image Explanations: A Case Study On Ex-vivo Kidney Stone Images
Raina et al. BoMBR: An Annotated Bone Marrow Biopsy Dataset for Segmentation of Reticulin Fibers